Exciting Research Update!
Our HEAL partner SERO at the Austrian Red Cross in Vienna/ Austria, has published a new article in Frontiers in Immunology!
Read the article here:
https://www.frontiersin.org/articles/10.3389/fimmu.2026.1736994
Congratulations to Dirk Strunk and team!
#HEAL_Horizon_EU #AustrianRedCross #DirkStrunk #RegenerativeMedicine
Frontiers | Deep immune-phenotyping of HLA-homozygous iPS-cardiomyocytes by spectral flow cytometry
IntroductionImmunogenicity of allogeneic human induced pluripotent stem cell (hiPSC)-derived transplants limits their applicability in regenerative medicine....
Please also check our website:
https://www.heal-horizon.com 😍
Meet the partner: Catalent Düsseldorf GmbH (Germany), Universitair Medisch Centrum Utrecht (Netherlands), Paracelsus Medizinische Privatuniversitat (Austria), Austrian Red Cross (SERO), the Hebrew University of Jerusalem (Israel), Biological Industries Ltd. (Israel), European Infrastructure for Translational Medicine (Europe), InnoSER (Belgium), Heinrich-Heine-University Düsseldorf (Germany) and the University of Oxford (United Kingdom).
Meet the
#HEAL team! Led by Dr. Robert Zweigerdt & Prof. Dr. Ulrich Martin (MHH, Germany), the project brings together 10 partners from Europe & Israel
#HEALproject #celltherapyExciting news from the
#HEAL project! The EU is funding a groundbreaking research project to develop a new cell therapy for regenerating damaged hearts. Led by Medical School Hannover, the project aims to overcome scientific, regulatory & safety hurdles for a first-in-man clinical trial.
#celltherapy #heartdisease #regenerativemedicine #HEALprojectWhat does the acronoym HEAL mean: HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technologies for allogenic cell therapy to the heart:
The European Union is funding the HEAL research project, which involves ten partners from all over Europe and Israel, with more than six million euros, of which the Medical School Hannover (MHH) is the coordinating institution.
